Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1993 Sep;93(3):301–307. doi: 10.1111/j.1365-2249.1993.tb08176.x

In vivo treatment with a monoclonal chimeric anti-CD4 antibody results in prolonged depletion of circulating CD4+ cells in chimpanzees

M Jonker, W Slingerland, G Treacy, P van Eerd, K Y Pak, E Wilson, S Tam, K Bakker, A F Lobuglio, P Rieber, G Riethmuller, P E Daddona, J Iuliucci
PMCID: PMC1554916  PMID: 8103714

Abstract

Chimeric M-T412 (cM-T412), an anti-CD4 antibody, was tolerated in chimpanzees at a dosage of 5 mg/kg per day for up to 7 consecutive days, or 5 mg/kg per dose, twice weekly for 4 weeks. All cM-T412-treated chimpanzees showed a prolonged CD4 cell depression. Weak chimpanzee antibody responses to chimeric M-T412 were observed. One of the chimpanzees on the biweekly dosage regimen exhibited a hypersensitivity reaction immediately after receiving its seventh dose. Following supportive treatment, the animal recovered and remained asymptomatic during the non-treatment observation period. The hypersensitivity reaction was not an unexpected response considering the animal received repeated intermittent i.v. administration of a foreign protein. This animal also showed a chimpanzee antibody response to chimeric M-T412 after the seventh dose. Chimeric M-T412 also induced an anti-cM-T412 response in some of the other animals. The level of this response was lower than the anti-mouse responses observed in animals treated with murine anti-CD4. Moreover, the anti-cM-T412 response was mainly directed to idiotypic determinants. The decrease in CD4+ cells observed for all chimeric M-T412-treated chimpanzees is an expected effect of the anti-CD4 antibody. The duration of this CD4+ cell decrease is, however, much longer than observed for other CD4-specific MoAbs described. No selective loss of either memory or naive CD4+ cells was observed after either the single, 7-day or twice-weekly treatments. The CD4+ cell depression was reversible, although individual variation in time to recovery was observed. Therefore, cM-T412 could be a good candidate for clinical use in autoimmune conditions.

Full text

PDF
301

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bakker N. P., van Erck M. G., Botman C. A., Jonker M., 't Hart B. A. Collagen-induced arthritis in an outbred group of rhesus monkeys comprising responder and nonresponder animals. Relationship between the course of arthritis and collagen-specific immunity. Arthritis Rheum. 1991 May;34(5):616–624. doi: 10.1002/art.1780340514. [DOI] [PubMed] [Google Scholar]
  2. Brostoff S. W., Mason D. W. Experimental allergic encephalomyelitis: successful treatment in vivo with a monoclonal antibody that recognizes T helper cells. J Immunol. 1984 Oct;133(4):1938–1942. [PubMed] [Google Scholar]
  3. Choy E. H., Chikanza I. C., Kingsley G. H., Panayi G. S. Chimaeric anti-CD4 monoclonal antibody for relapsing polychondritis. Lancet. 1991 Aug 17;338(8764):450–450. doi: 10.1016/0140-6736(91)91076-7. [DOI] [PubMed] [Google Scholar]
  4. Goldberg D., Morel P., Chatenoud L., Boitard C., Menkes C. J., Bertoye P. H., Revillard J. P., Bach J. F. Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis patients. J Autoimmun. 1991 Aug;4(4):617–630. doi: 10.1016/0896-8411(91)90181-b. [DOI] [PubMed] [Google Scholar]
  5. Hafler D. A., Ritz J., Schlossman S. F., Weiner H. L. Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human anti-mouse responses. J Immunol. 1988 Jul 1;141(1):131–138. [PubMed] [Google Scholar]
  6. Herzog C., Walker C., Pichler W., Aeschlimann A., Wassmer P., Stockinger H., Knapp W., Rieber P., Müller W. Monoclonal anti-CD4 in arthritis. Lancet. 1987 Dec 19;2(8573):1461–1462. doi: 10.1016/s0140-6736(87)91158-5. [DOI] [PubMed] [Google Scholar]
  7. Jonker M., Den Brok J. H. Idiotype switching of CD4-specific monoclonal antibodies can prolong the therapeutic effectiveness in spite of host anti-mouse IgG antibodies. Eur J Immunol. 1987 Nov;17(11):1547–1553. doi: 10.1002/eji.1830171104. [DOI] [PubMed] [Google Scholar]
  8. Jonker M., Neuhaus P., Zurcher C., Fucello A., Goldstein G. OKT4 and OKT4A antibody treatment as immunosuppression for kidney transplantation in rhesus monkeys. Transplantation. 1985 Mar;39(3):247–253. doi: 10.1097/00007890-198503000-00006. [DOI] [PubMed] [Google Scholar]
  9. Koike T., Itoh Y., Ishii T., Ito I., Takabayashi K., Maruyama N., Tomioka H., Yoshida S. Preventive effect of monoclonal anti-L3T4 antibody on development of diabetes in NOD mice. Diabetes. 1987 Apr;36(4):539–541. doi: 10.2337/diab.36.4.539. [DOI] [PubMed] [Google Scholar]
  10. LoBuglio A. F., Wheeler R. H., Trang J., Haynes A., Rogers K., Harvey E. B., Sun L., Ghrayeb J., Khazaeli M. B. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A. 1989 Jun;86(11):4220–4224. doi: 10.1073/pnas.86.11.4220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Nicolas J. F., Chamchick N., Thivolet J., Wijdenes J., Morel P., Revillard J. P. CD4 antibody treatment of severe psoriasis. Lancet. 1991 Aug 3;338(8762):321–321. doi: 10.1016/0140-6736(91)90465-2. [DOI] [PubMed] [Google Scholar]
  12. Prinz J., Braun-Falco O., Meurer M., Daddona P., Reiter C., Rieber P., Riethmüller G. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet. 1991 Aug 3;338(8762):320–321. doi: 10.1016/0140-6736(91)90464-z. [DOI] [PubMed] [Google Scholar]
  13. Ranges G. E., Sriram S., Cooper S. M. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med. 1985 Sep 1;162(3):1105–1110. doi: 10.1084/jem.162.3.1105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Reiter C., Kakavand B., Rieber E. P., Schattenkirchner M., Riethmüller G., Krüger K. Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. Clinical results and immunopharmacologic effects in an open study, including repeated administration. Arthritis Rheum. 1991 May;34(5):525–536. doi: 10.1002/art.1780340504. [DOI] [PubMed] [Google Scholar]
  15. Waldor M. K., Sriram S., Hardy R., Herzenberg L. A., Herzenberg L. A., Lanier L., Lim M., Steinman L. Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Science. 1985 Jan 25;227(4685):415–417. doi: 10.1126/science.3155574. [DOI] [PubMed] [Google Scholar]
  16. Wofsy D., Seaman W. E. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med. 1985 Feb 1;161(2):378–391. doi: 10.1084/jem.161.2.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wraith D. C., McDevitt H. O., Steinman L., Acha-Orbea H. T cell recognition as the target for immune intervention in autoimmune disease. Cell. 1989 Jun 2;57(5):709–715. doi: 10.1016/0092-8674(89)90786-1. [DOI] [PubMed] [Google Scholar]
  18. van Lambalgen R., Jonker M. Experimental allergic encephalomyelitis in rhesus monkeys: I. Immunological parameters in EAE resistant and susceptible rhesus monkeys. Clin Exp Immunol. 1987 Apr;68(1):100–107. [PMC free article] [PubMed] [Google Scholar]
  19. van der Lubbe P. A., Miltenburg A. M., Breedveld F. C. Anti-CD4 monoclonal antibody for relapsing polychondritis. Lancet. 1991 Jun 1;337(8753):1349–1349. doi: 10.1016/0140-6736(91)93023-3. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES